drugset / Trial / NCT02469896
A Trial of Tocilizumab in ALS Subjects
Phase 2
Completed
22 enrolled
Barrow Neurological Institute
ALS Association · collabBarrow Neurological Foundation · collabGenentech, Inc. · collabMassachusetts General Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS). The investigators also want to find out if tocilizumab is safe to take without causing too many side effects. Currently ALS has no cure and 2 modestly effective treatment to slow the progression of the disease. Although not the initial cause of ALS, the immune system plays a role in the death of motor neurons. The immune cells that participate in this process are stimulated by a substance called interleukin-6 (IL-6) whose effect is blocked by tocilizumab and thus, may slow the death of motor neurons and slow the disease.
Timeline
- Start
- 2015-11
- Primary completion
- 2018-07-11
- Completion
- 2018-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |